Evidence map›Paper›PMID 30917179›Full record

ArticlePloS one2019

Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes.

Kevin D Schuster, Mohammadjavad Mohammadi, Karyn B Cahill, Suzanne L Matte, Alexis D Maillet, Harish Vashisth, Rick H Cote

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Coupling of conformational dynamics and inhibitor binding in the phosphodiesterase-5 family.Protein science : a publication of the Protein Society · 2023
    Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kevin D SchusterDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States of America.
Mohammadjavad MohammadiDepartment of Chemical Engineering, University of New Hampshire, Durham, NH, United States of America.ORCID 0000-0001-7344-0857
Karyn B CahillDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States of America.
Suzanne L MatteDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States of America.
Alexis D MailletDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States of America.
Harish VashisthDepartment of Chemical Engineering, University of New Hampshire, Durham, NH, United States of America.
Rick H CoteDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, United States of America.ORCID 0000-0002-1573-6526
University of New Hampshire · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel chemical controls are needed that selectively target human, animal, and plant parasitic nematodes with reduced adverse effects on the host or the environment. We hypothesize that the phosphodiesterase (PDE) enzyme family represents a potential target for development of novel nematicides and anthelmintics. To test this, we identified six PDE families present in the nematode phylum that are orthologous to six of the eleven human PDE families. We characterized the binding interactions of family-selective PDE inhibitors with human and C. elegans PDE4 in conjunction with molecular dynamics (MD) simulations to evaluate differences in binding interactions of these inhibitors within the PDE4 catalytic domain. We observed that roflumilast (human PDE4-selective inhibitor) and zardaverine (selective for human PDE3 and PDE4) were 159- and 77-fold less potent, respectively, in inhibiting C. elegans PDE4. The pan-specific PDE inhibitor isobutyl methyl xanthine (IBMX) had similar affinity for nematode and human PDE4. Of 32 residues within 5 Å of the ligand binding site, five revealed significant differences in non-bonded interaction energies (van der Waals and electrostatic interaction energies) that could account for the differential binding affinities of roflumilast and zardaverine. One site (Phe506 in the human PDE4D3 amino acid sequence corresponding to Tyr253 in C. elegans PDE4) is predicted to alter the binding conformation of roflumilast and zardaverine (but not IBMX) into a less energetically favorable state for the nematode enzyme. The pharmacological differences in sensitivity to PDE4 inhibitors in conjunction with differences in the amino acids comprising the inhibitor binding sites of human and C. elegans PDE4 catalytic domains together support the feasibility of designing the next generation of anthelmintics/nematicides that could selectively bind to nematode PDEs.

Indexed as

Molecular Dynamics SimulationAmino Acid SequenceAnimalsAntinematodal AgentsCaenorhabditis elegansCyclic Nucleotide Phosphodiesterases, Type 4HumansPhosphodiesterase 4 InhibitorsProtein BindingProtein ConformationAntinematodal AgentsCyclic Nucleotide Phosphodiesterases, Type 4Phosphodiesterase 4 Inhibitors

Identifiers

PMID30917179
PMCPMC6436744
OpenAlexW2923251896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.